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PEG200
Synperonic® PE/L-61The purpose of the study is to investigate dissolution behaviour of norﬂoxacin as a model hydrophobic drug
through application of liquisolid technology. Norﬂoxacin was prepared as liquisolid formulations using either
ﬂowability or compressibility liquisolid tests. The dissolution proﬁles were evaluated and compared to
counterpart conventional norﬂoxacin tablets. Two non-volatile liquid vehicles were used in the preparation of
norﬂoxacin liquisolid formulations; Poly Ethylene Glycol (PEG200) and Synperonic PE/L-61. The liquisolid
formulations of norﬂoxacin were tested according to the speciﬁcation of British Pharmacopoeia (BP) quality
control tests. Moreover, the pre-preparation evaluation tests, such as powder ﬂowability Carr index, differential
scanning calorimetry (DSC) and Fourier transform infrared (FT-IR), were applied for further investigation of the
physicochemical properties of the liquisolid formulations. The results indicated that the percentage of
norﬂoxacin release in acetate buffer solution (pH = 4.0) is higher than in distilled water. Also, at the ﬁrst
20 min, the percentage of the drug release is higher only in the decreased amount of liquid vehicle formulations
compared with the conventional tablet. Generally, the conventional tablet dissolution proﬁle is either similar or
higher than liquisolid tablets. Moreover, Synperonic PE/L-61 liquisolid tablets showed higher dissolution proﬁles
than PEG200 liquisolid tablets, although the solubility of norﬂoxacin in PEG200 (2.507 mg/ml) is much higher
than in Synperonic PE/L-61 (0.167 mg/ml). In conclusion, increasing the percentage of liquid vehicle in the
prepared norﬂoxacin liquisolid formulations does not necessarily lead to increase in the percentage of the drug
release in distilled water dissolution medium.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Oral delivery administration can be considered as a frequently
employed route among drug delivery systems. This is due to its cost
effectiveness, least sterility restrictions during manufacturing, ease of
administration and ﬂexibility of formulation design. Consequently,
several pharmaceutical companies select bioequivalence oral drug
production preferably [1].
Oral compacts, containing poor water soluble drugs, usually involve
high doses in order to increase therapeutic plasma concentration level
after oral administration. Low level of solubility does not help to attain
therapeutic levels. Thus, it is considered as a major problem facing any
formulation design for both new chemical entities and generic develop-
ment [2].
According to bio-pharmaceutics classiﬁcation system (BCS), more
than 40% of drugs are poorly water soluble drugs. These drugs have
slow absorption toward plasma, leading to not only low and inadequateepartment of Pharmacy, Health
152576; fax: +44 1915153405.
Elkordy).bioavailability, but also raise the toxicity in gastrointestinal mucosa due
to its accumulation in GI track. As a result, the improvement of drug
solubility and dissolution is one of the major goals to enhance oral
bioavailability [3].
Recent new synthesized drugs show an increase in the number of
hydrophobic groups, which have difﬁculties in oral delivery due to
their poor solubility and bioavailability. An example of these drugs is
norﬂoxacin. It is used to treat urinary tract infections because it works
as a chemotherapeutic antibacterial agent. Only 30–40% of norﬂoxacin
can be absorbed through passive diffusion [4]. Moreover, in vitro tests,
using either non-everted intestinal sacs or caco-2 cells, recorded
low permeability percentage, conﬁrming norﬂoxacin classiﬁcation as a
poorly permeable compound [5].
In addition to this, norﬂoxacin can be classiﬁed as a zwitterionic
molecule. It represents a U-shaped proﬁle in terms of pH-solubility
studies—a high solubility when pH is less than 5, low solubility in
neutrality region, and a high again when pH is over 10. As a result, it is
classiﬁed as a low water soluble drug [6].
One method used to enhance both solubility and dissolution of
hydrophobic drugs is liquisolid pharmaceutical technique. The deﬁni-
tion of liquisolid systems is “they are compacts with acceptable ﬂowing
157A.S. Suliman et al. / Powder Technology 257 (2014) 156–167and compressible powdered forms of liquidmedications,which represent
oily liquid drugs and solutions or suspensions of water insoluble solid
drugs carried in suitable non-volatile solvent systems termed the liquid
vehicles” [7]. According to this deﬁnition, liquisolid method can be
selected to improve the water solubility of norﬂoxacin.
A range of several surfactants has been selected, in this study, for
liquisolid preparations. The selection stands on covering a wide range
of Hydrophobic Lipophilic Balance (HLB) values. For example, poly
ethylene glycol 200 (PEG 200), which has HLB value = 18.1 and
poloxamer 181 copolymer (Synperonic PE/L-61) with HLB = 3.
Regarding PEG200, it is a stable-hydrophilicwater-miscible surfactant.
It can be used as a suspending agent to form liquid medication with a
hydrophobic drug that allows miscibility in water. A wider view to poly
ethylene glycol surfactants determines an advantage for the lowmolecu-
lar weight group, which increases the rate of the drug release from liquid
medication. On the other hand, the higher molecular weight, more
enhancement of the effectiveness of compact binder, even though when
the concentration is over 5%, could prolong the disintegration. In general,
PEGs are stable in both air and solution. However, the low grades of PEG
demonstrate a level of hygroscopicity. In conclusion, PEGs can be consid-
ered as a good solvent to prepare immediate release liquisolid formula-
tions [8].
Another example is Poloxamer 181, which represents the group of
low HBL value liquid vehicles. The chemical structure consists of three
synthetic blocks, representing hydrophilic and lipophilic parts. The
ﬁrst and the third blocks are two poly (oxyethylene) groups from
each side, while the middle block is thirty poly (oxypropylene) groups.
This structure allows the surfactant to be more hydrophobic with HLB
value = 3. The general use of poloxamers is as binders or coaters in
tablet production. However, the physical properties and viscosity of
these surfactants change depending on the length chain of hydrophobic
and hydrophilic blocks. Also, poloxamers are stable if they present
in acids, alkaline or metal ions. They are classiﬁed as non-toxic and
non-irritant substances. As a result, the physicochemical properties
make them good candidates to be used in liquisolid formulations [8].
The concept of liquisolid system stands on two fundamental terms;
the ﬂowable Ø value and compressible ψ number liquid retention
potentials. TheØ value deﬁnes an acceptable level of powder ﬂowability
when adding the maximum amount of a given non-volatile liquid,
whereas the ψ number speciﬁes an acceptable level of powder com-
pressibility when adding the maximum amount of the non-volatile
liquid. Spireas et al. indicated two methods to predict the two terms.
The ψ number and Ø values are determined by applying liquisolid
compressibility (LSC) test and liquisolid ﬂowability (LSF) test, respec-
tively [7].
Regarding the LSF test, several powder systems are prepared to con-
tain different values of excipient ratio (R) where R = Q/q; Q represents
theweight of a carrier excipient and q represents the weight of a coating
excipient. Eachmixturewill contain an increased amount of non-volatile
liquid which will be used in liquisolid preparation. The ﬂowability of
each prepared mixture will be assessed by ﬂow metre, angle of slid,
angle of repose or any suitable ﬂowability test to specify the ﬂowable
liquid load factor ØLf of each powder system. The ØLf can be given by
the following equation
KL f ¼W=Q ;where W is the weight of the liquid vehicle and Q is the
weight of the carrier material:
Finally, Ø value of a powder (carrier or coating excipients) will be
determined by plotting ØLf against reciprocal excipient ratio (1/R)
where the slope represents Ø value of the carrier and the intercept
indicates the Ø value of the coating.
In liquisolid compressibility (LSC) test, the same liquid/powder
admixture prepared in the previous test will be used to assess the
maximum crushing strength of the compacts that can be obtained byapplying a plateau compression forces. The average of crushing strength
of each admixture will be divided on the average of the weight of the
compacted tablets in order to determine the pactisity Ω value. The
determination of the net liquid/solid weight composition (Cw) of the
crushed tablets will be used to indicate the intrinsic pactisity (Ωo)
and sponge index (σi) by plotting log Ω versus Cw to give a log-linear
equation: log Ω= log Ωo− σi ∗ Cw.
The compressible liquid retention potential of the powder system
(ψmix) can be given by the following equation ψmix = (log Ωo− log
20) / σi, where the ﬁxed value of the logarithm twenty comes from
applying the plateau force pressures to achieve the maximum crushing
strength which gives a pactisity Ω= 20 kg/g.
Finally, the compressible liquid load factor (ψLf) of the powder
system can be determined from the following equation: ψLf = ψmix
(1 + 1/R). By plotting the ψLf for each admixture against the reciprocal
excipient ratio (1/R) will give a linear equation with a slope equals to
compressible liquid-retention potential (ψ number) of the carrier and
the intercept is the compressible liquid-retention potential (ψ number)
of the coating.
The optimum load factor (Lo), which will be used to determine the
optimum quantities of the carrier and coating excipients, will indicate
the acceptable ﬂowing and compressible liquisolid system. This term
is given as follows;
Lo ¼ KL fwhenKL fbψLf
or
Lo ¼ ψL fwhenKL fNψLf
where ØLf = Øca + Øco ∗ (1/R) and ψLf = ψca + ψco ∗ (1/R).
The optimum quantity of the carrier Qo is given from this equation:
Qo = W/Lo; where W= weight of drug/weight of non-volatile liquid.
Finally, the optimum quantity of the coating material qo is given as
follows: qo = Qo/R. All the mathematical calculation is mentioned in
this article [7].
2. Materials and methods
2.1. Materials
Norﬂoxacinwas obtained fromSigma-Aldrich, Co., UK. Other powder
excipients used to prepare the tablets include microcrystalline cellulose
(AvicelPH101), (FMC Biopolymer Corp., Philadelphia, USA); colloidal
silicon dioxide (Cab-O-Sil® M-5 DP, particle size: 0.2–0.3 lm),
(Cabot GmbH, Werk Rheinfelden, Germany); croscarmellose sodi-
um USP/NF/EP (Vivasol®), (CHP Carbohydrate Pirna GmbH & Co.
KG, Pirna, Germany); magnesium stearate (MEDEX, Morthants).
The surfactants used in screening solubility tests are Propylene
Glycol (Sigma-Aldrich, Germany); Sorbitan Monooleate (Span 80)
(Sigma-Aldrich, Germany); Polyethylene Glycol 200 (Sigma-Aldrich,
USA); Sorbitan Monolaurate (Span 20) (Sigma-Aldrich, South Korea);
Synperonic PE/L61 (ICI surfactants, Everberg, Belgium); PolyethyleneGly-
col 400 (Sigma-Aldrich, Belgium); Cremophore EL (poly-oxy-35-castor
oil)(BASF, Germany); pluronic®L-35 (Sigma-Aldrich, USA); Polyethylene
Glycol 300 (Sigma-Aldrich, Germany); Tween 80 viscous liquid (Sigma-
Aldrich, UK); Tween 20 viscous liquid (sigma-Aldrich, France).
Acetic acid (Sigma-Aldrich, UK) with Sodium Hydroxide pellets
(Sigma-Aldrich, UK) were used for acetate buffer solution (pH = 4.0)
preparation. Orthophosphoric acid HPLC electrochemical grade (Fisher
Scientiﬁc, UK) with Acetonitrile HPLC grade (Fisher Scientiﬁc, UK)
were used together in drug content uniformity test.
Finally, buffer tablets pH = 4.0(BDH Chemical Ltd., England) and
Buffer tablets pH = 7.0 (Asons Laboratory reagent, UK) are used for
Fig. 2. The optimumﬂowability value for Synperonic PE/L-61 and Avecil PH101 admixture
(0.3) and Synperonic PE/L-61 with Cab-o-sil M5DP admixture (0.2).
158 A.S. Suliman et al. / Powder Technology 257 (2014) 156–167calibrating Jenway 3505 pHmetre. Allmaterialswere of pharmacological
or analytical grade.
2.2. Pre-formulation studies
2.2.1. Solubility studies
The solubility of norﬂoxacin in several surfactants, which are PEG200,
PEG300, PEG400, Span 20, Span 80, Tween 20, Tween 80, Synperonic PE/
L61, Pluronic L-35, Propylene Glycol and Cremophore EL as well as
distilled water, was performed to evaluate the drug solubility of
the non-volatile liquid vehicles as solvent and suspending agents for
norﬂoxacin. Saturated solutionswere prepared by adding excess amount
of norﬂoxacin into 1 ml of each liquid vehicle. The resulting solutions
were sealed and kept at room temperature (24 ± 1 °C) for 72 h. After
this period, the solutions were centrifuged using a centrifuge rotor
(Mikro 12–24, Hettich, Germany) for 10 min, at 4000 U/min. The super-
natants were transferred to 1 ml eppendorf tubes and re-centrifuged
until no drug particles precipitate. The drug concentration in each super-
natant was determined using a single beam UV/Vis spectrophotometer
(Model M501, Camspec LTD, Cambridge, UK) at 318 nm after dilution in
acetonitrile as appropriate. The concentration of norﬂoxacin in each liq-
uid vehicle was calculated based on the calibration curve of norﬂoxacin.
2.2.2. Determination of optimal ﬂowable liquid-retention potential
(ϕ-value)
The angle of slide measurement (Figs. 1 and 2) was used to deter-
mine the optimal ﬂowable liquid-retention potential (ϕ-value) of each
powder excipient (Avicel® PH101 and Cab-o-Sil® M-5 DP) with
Synperonic® PE/L61 and PEG200. Each powder excipients (2.5 g) was
mixed with increasing amounts of the two non-volatile liquid vehicles,
and the resulting admixture was placed on an edge of a polished metal
plate, tilted gradually until the admixture starts to slide. The angle of
the plate with the horizontal surface is deﬁned as the angle of slide. The
ϕ-value of Avicel® PH101 and Cab-o-sil®M-5 DP in different concentra-
tions of liquid vehicles was calculated based on the following equation:
ϕ‐value ¼ weight of the liquid vehicle=weight of solid:
The calculated ϕ-values against the resulting angle of slides were
plotted to select the optimum ϕ-value of the powder excipient in the
corresponding liquid vehicle at 33°. However, all corresponding angles
were less than 33°, so the nearly highest anglewas selected to represent
the optimum ﬂowability number [11].Fig. 1. The optimum ﬂowability value for PEG200 and Avecil PH101 admixture (0.2) and
PEG200 with Cab-o-sil M5DP admixture (0.2).2.2.3. Determination of compressibility liquid-retention potential (Lf
Ψ)
Powder systems consisting ofAvicel PH101 andCab-o-silM5DPat dif-
ferent excipient ratios; R=10 and R=20;where R equals to theweight
of AvicelPH101divided byweight of Cab-o-sil M5DPwere preparedwith
increasing amount of Synperonic® PE/L61. Firstly, the mixtures without
the liquid vehicle were compressed by Manesty Type 3 single punch
compactor at a speciﬁc weight and a compression force to give the max-
imum tablet hardness, which are measured by Schleuniger-2E hardness
tester. Then, the liquid vehicle was added gradually to give different
liquid/solid weight compositions (Cw). The pactisity (Ω) of each admix-
ture is calculated by dividing the average hardness of tablets on the aver-
age weight of the crushed tablets. By determining the average liquid
content of the crushed compacts and calculating the net liquid/solid
weight composition (Cw) of the crushed liquid/powder admixture, a
plot of Cw against log-pactisity to determine the characteristic intrinsic
pactisity (Ωo) as an index (σ0) of the powder system, where
logΩ ¼ logΩo−σ0  Cw:
The compressible liquid retention potential (Ψ-number) of the pow-
der system (Ψmix) was calculated according to the following equation:
Ψmix ¼ logΩo− log20
σ0
:
Finally, by calculating the Ψmix value for each powder system, the
compressible liquid-load factor (LfΨ) of the mixture of Synperonic®
PE/L61 with powder excipient (Avicel PH101 and Cab-o-sil M5DP) at
speciﬁc excipient ratios (R) was determined according to the following
equation:
LΨf ¼ Ψmix 1þ
1
R
 
:
This method was applied simulating Liquisolid Compressibility
(LSC) Test [7].
2.3. Liquisolid formulations and compact preparations
The calculated amounts of both carrier and coatingmaterials in each
liquisolid formulations were determined according to the ﬂowability
numbers for the formulations containing PEG200 and compressibility
liquid load factor for the Synperonic PE/L-61 formulations. The reason
for choosing the compressibility liquid load factor in these formulations
is the lower value obtained comparedwith ﬂowability liquid load factor
for the same formulations. However, this is not applied for PEG200
formulations due to the ability to compact the powder at ﬂowability
liquid load factor and obtain acceptable compacts, which means it is
159A.S. Suliman et al. / Powder Technology 257 (2014) 156–167less than the corresponding compressibility liquid load factor for the
same formulations [7].
The equation used to calculate the ﬂowability liquid load factor is:
Lϕf ¼ ϕcar þ ϕco 1R
 
, where ϕcar and ϕco is the ﬂowability number of
the carrier and coating respectively, which are determined form
the highest angle of slide under 33°.
The excipient ratio (R) was chosen to be either 10 or 20 for all
liquisolid formulations. Moreover, 20 mg of norﬂoxacin active ingredi-
ent was selected to be in each tablet. As a result, the required amount
of liquidmedication (W) is calculated depending on drug concentration
in the liquid medication (i.e. 20%w/w or 40%w/w). After determining
the liquid load factor, the desired amount of carrier can be calculated
by applying the following equation: Lf ¼ WQ and the speciﬁc amount of
coating is form R = Q / q. The liquisolid and conventional formulations
are summarised in Table 1.
The detailed procedure for liquisolid formulation preparation is as
follows; ﬁrstly, pure norﬂoxacin was dispersed in the liquid vehicle
(PEG200 or Synperonic® PE/L61) to form a liquid medication. Then,
the carrier (Avicel PH101) and the coating (Cab-o-sil M5DP) excipients
were added to the liquid medication with continuous mixing by mortar
and pestle until obtaining a dry powder mixture.
Carmellose sodium disintegrant (5% w/w of the unit dose) and mag-
nesium stearate lubricant (1% w/w of the unit dose) were added to the
liquisolidmixturewith continuousmixing until reach to a homogeneous
mixture.
Finally, all formulationswere compacted into tablets using the single
punch tablet press with acceptable level of hardness. For high unit dose
weight, each sample unit was divided into 2 or 4 tablets so that they
contain 20 mg of norﬂoxacin. The reason for this is to ensure that each
tablet is within a reasonable size and hardness.
By using mortar and pestle, the conventional norﬂoxacin tablets
were prepared by mixing carrier and coating (R = 20) with 20 mg of
the drug and with the same percentage of lubricant and disintegrant.
The resulting powder mixture was directly compressed into tablets
through the single punch compactor.2.4. Pre-compression studies
2.4.1. Determination of ﬂow property
Assessing the ﬂowability of prepared liquisolid powders depends on
Carr's Compressibility Index (CI). It is calculated from determination of
the relative poured bulk density (Pb) and the tapped density (Pt) of
each liquisolid powder formulation. Theweight of each liquisolid powder
formulationwas recorded and then the powderwas poured into a 250ml
cylinder on a tap volumeter (JV1000, Copley Scientiﬁc, UK). Both poured
bulk volume (Vb) and tapped volume (Vt), which is the constant volume
obtained after application of a sufﬁcient number of taps (usually after 500
taps × 3 times), are recorded. The densities are determined fromdividingTable 1
The percentage of liquisolid and conventional tablet formulations.
Formula Non-volatile
liquid vehicle
Drug conc. in liquid
vehicle (%w/w)
R value Liquid vehicle mg Drug m
1 PEG 200 20 10 80 20
2 PEG 200 20 20 80 20
3 PEG 200 40 10 30 20
4 PEG 200 40 20 30 20
5 S-L-61a 20 10 80 20
6 S-L-61 20 20 80 20
7 S-L-61 40 10 30 20
8 S-L-61 40 20 30 20
Conventional – – – – 20
a S-L-61: Synperonic PE/L-61.eachweight of the liquisolid powder on the relative volume. Finally, %CI is
calculated by applying the following equation [9]
%CI ¼ 100 Pt−Pbð Þ=Pt :
2.4.2. Differential scanning calorimetry (DSC)
Pure norﬂoxacin and all liquisolid and conventional powders were
exposed to DSC scan via DSC Refrigerated Cooling System (Model
Q1000, TA Instruments, UK). Each sample contained about 3–6 mg.
Then, it was hermitically sealed in an aluminium pan before analysis.
Two samples of indium (10 and 12mg) were used to validate the accu-
racy of the instrument. The investigation of the thermal behaviour of
each sample was at a scanning rate 10 °C/min, from 0 °C to 300 °C.
2.4.3. Fourier transform infrared spectroscopy (FTIR)
Infrared spectra were acquired for norﬂoxacin, Synperonic® PE/L61,
PEG200, Avicel® PH101, Cab-o-sil®M-5DP, Vivasol®,magnesium stea-
rate and all liquisolid and conventional formulations using SpectrumBX
FTIR Spectrophotometer (Perkin–Elmer, Cambridge, UK). Small amount
of each sample was directly loaded into the instrument without any
treatments. The frequency ranged from 2000 cm−1 to 600 cm−1 at
1.0 cm−1 resolution. The data was obtained by Spectrum BX series
software version 5.3.1 and transferred to Microsoft Excel®.
2.5. Evaluation of norﬂoxacin liquisolid tablets
2.5.1. Drug content uniformity, tablet dimensions, hardness, tensile strength,
friability and disintegration tests
For content uniformity test, tablets containing 20 mg of norﬂoxacin
were weighed and crushed by mortar and pestle in order to determine
the drug content in liquisolid and conventional tablets. Then, the
crushed powder was dissolved in a suitable solvent; acetate buffer
solution at pH = 4 for tablets containing Synperonic PE/L-61 and a
prepared mixture of acetonitrile with orthophosphate buffer pH = 4
(150 ml: 750 ml). The result solutions were mixed for 1 h and ﬁltered.
Finally, the samples were analysed for determining the drug concentra-
tion using UV spectrophotometer at 315 nm. The percentage of drug
content with respect to the theoretical amount was determined.
Tablets friability was measured using a Comply FRV 1000 friability
tester and disintegration times were determined employing Coply
DTG200 disintegration tester at 37 °C in distilledwater. Tablet thickness
and diameter were determined by micrometre (Moor and Wright,
England). Tensile strengths of tablets were calculated by applying the
following equation:
S ¼ 2P
Π
 d tg Carrier mg Coating mg Liquid load
factor Lf
Disintegrant
mg (~%5)
Lubricant
mg (~%1)
Unit dose mg
454.55 45.45 0.22 31.91 6.38 638.30
476.19 23.81 0.21 31.91 6.38 638.30
227.27 22.73 0.22 15.96 3.19 319.15
238.10 11.90 0.21 15.96 3.19 319.15
716.93 71.69 0.14 47.27 9.45 945.35
962.64 48.13 0.10 59.08 11.82 1181.68
358.47 35.85 0.14 23.63 4.73 472.67
481.32 24.07 0.10 29.54 5.91 590.84
254.45 25.50 – 16.00 3.20 319.15
160 A.S. Suliman et al. / Powder Technology 257 (2014) 156–167where S is the tensile strength, P is the crushing forcewhich determined
by Schleniger-2E hardness tester, d is the diameter of the tablet and t is
the tablet thickness.
2.5.2. In vitro dissolution studies
In vitro dissolution studies were performed for pure norﬂoxacin,
conventional and all liquisolid tablet formulations by using USP dissolu-
tion apparatus II (Caleva 8ST Ltd., Dorset, UK). Two different dissolution
media were used for all liquisolid and conventional tablets; distilled
water (pH = 6.1) and the acetate buffer solution (pH = 4.0). Both
medium volumes were 750 ml with a paddle speed 50 rpmmaintained
at 37 °C according to BP speciﬁcations [9]. 10ml samplewaswithdrawn
at time intervals of 5, 10, 15, 20, 25, 30, 45, 60 and 90min, and thewith-
drawn sampleswere replacedwith equal volumes of the dissolutionme-
dium. Thedrug content in eachwithdrawn samplewas determinedusing
UV/Vis spectrophotometer (Model M501, Camspec Ltd., Cambridge, UK)
at 315 nm for acetate buffer medium and 321 nm for distilled water
medium. The reported data are an average of three samples with the
relevant standard deviation and the calibration curve was used to calcu-
late the relative drug concentration. Each sample included a number of
tablets (i.e. one, two or four tablets) so that it contains 20mgof the active
ingredient. This idea was taken from a similar study [12]. The similarity
factor (f2) was used as a statistical technique to compare between the
dissolution proﬁles.
f 2 ¼ 50 log 1þ 1n
 
Σnt¼1 Rt−Ttð Þ2
h i−0:5
 100
 
, where Rt is the reference
data, Tt is the test data, n is the number of samples. If the percentage is
over 50%, this means that the two groups of data are similar; otherwise
it is not signiﬁcantly similar.
2.5.3. Kinetic model analysis of drug release
In order to inspect the mechanism of norﬂoxacin release from
liquisolid and conventional tablets, several kinetic release models
were applied on data obtained from dissolution tests. These models
are; zero order, ﬁrst order, and Higuchi and Hixson–Crowell kinetic
models. Regarding zero order model, it can be described as a system
that all drug particles transfer process to dissolution medium that is
conﬁded to the surface area of the system. The data of the cumulative
percentage of the drug release can be plotted against the time [13]. In
terms of ﬁrst order, the drug release is related to the drug concentration
and it can be applied by plotting logarithm of the percentage release of
the remaining drug versus the time [13]. Moreover, in Higuchi model,
plotting the cumulative percentage of the drug release against the
square root of time should be linear if the drug release from the tablet
a controlled diffusion [14]. Furthermore, Hixson–Crowell model
depends on the theory that particle area is proportional to the cubic
root of its volume. As a result, the plotting data is the cubic root of the
drug remaining in the tablet versus the time [15]. The highest square
of correlation coefﬁcient (R2 value) was selected to indicate the most
appropriate model to represent the norﬂoxacin release from liquisolid
formulation [13]. Statistically, Paired t-tests were used to determine
whether there is a signiﬁcant difference between themodels, regardless
of the differences in the type of formulations. Due to dealingwithmodel
predictions, the signiﬁcant probabilitywas selected to bemore robust at
0.1 levels.
2.6. Statistical analysis
In the tests of evaluation norﬂoxacin tablet test (ﬂowability, friability,
hardness, tensile strength, content uniformity and disintegration tests),
Paired t-test was used to compare between the PEG200 liquisolid tablets
and Synperonic PE/L-61 liquisolid tablets, whereas One sample t-test
was used to compare between liquisolid tablets in general, PEG200
liquisolid tablets and Synperonic PE/L-61 liquisolid tablets in one side
and conventional tablet from the another side. All the data results were
quoted as signiﬁcant where P b 0.05.3. Results and discussions
3.1. Solubility studies
From Table 2, norﬂoxacin has the highest solubility value in PEG200,
whereas the lowest one is in Synperonic PE/L-61. It can be noticed that
with the increase in the molecular weight of the PEGs, the solubility of
norﬂoxacin decreases. Moreover, the drug has low solubilities with
both types of poloxamers (Synperonic PE/L-61 and Pluronic L-35),
although they have different HLB values, i.e. Pluronic L-35 is N20 and
Synperonic PE/L-61 equals to 3. The solubility of the drug in distilled
water is 0.34 mg/ml, allowing the drug to be classiﬁed as a very slightly
soluble one. The highest and the lowest solubility valueswere chosen to
be used in the liquisolid formulations to investigate the effect of the
solubility on the percentage of the drug release in the dissolution tests.
3.2. Pre-compression studies (characterization of powder admixtures)
3.2.1. Determination of ﬂow property
The importance of powder ﬂowability in tablet production comes
from its effect on the consistency of tablet weight and drug content.
One of the methods to determine the powder ﬂowability is Carr's com-
pressibility index, where the percentage of the differences between
bulk powder density before and after tapping divides on the bulk density.
This law was used to determine the ﬂowability of all liquisolid and con-
ventional formulations. The results are summarised in Table 3, and the
criteria dependonBritish Pharmacopoeia, indicating that any formulation
that has CI% below 25 represents better ﬂow properties [9]. The statistical
analysis shows that there is a signiﬁcant differences between liquisolid
formulations and conventional powder (P = 0.002 b 0.05). These differ-
ences come mainly from the difference between the Synperonic PE/L-61
formulations and conventional powder (P= 0.047 b 0.05). In general, all
liquisolid formulations recorded CI percentages over 20% and no signiﬁ-
cant differences between PEG200 liquisolid formulations and Synperonic
PE/L-61 liquisolid formulations (P = 0.406 N 0.05).
According to Spireas et al., the amount of carrier and coating mate-
rials in the liquisolid formulations determines the ﬂowability as they
play an important role in adsorbing the liquid vehicle on the surface of
the carrier, allowing coating particles specifying a certain amount of
retained liquid vehicle with an acceptable level of ﬂowability [16].
Consequently, the increasing amount of the liquid in the formulation
leads to increase the carrier and coating particles which enhance the
powder ﬂowability and reduce the %CI. This clearly appears in both
PEG200 and Synperonic PE/L-61 liquisolid formulations, wherever
there is a high percentage of the liquid, there is an increase in the
amount of carrier and coating. However, the low percentage of the
liquid vehicle leads to less amount of carrier and coating materials and
produces either poorly or very poorly ﬂowable formulations.
3.2.2. Differential scanning calorimetry (DSC)
Figs. 3 and 4 represent a comparison between all thermograms of
the liquisolid and conventional formulations with and without the
thermogram of pure norﬂoxacin. It is clear that norﬂoxacin pure drug
has a sharp endothermic peak at melting temperature (222.36 °C)
with relatively high enthalpy value (107.7 J/g). This sharp peak indi-
cates the crystallinity of the drug and the melting of the sample, refer-
ring the end of the thermogram to the decomposition of norﬂoxacin
[17]. Moreover, the sharp endothermic peak disappears in all liquisolid
formulations (PEG200 and Synperonic PE/L-61), indicating a change in
the crystallinity nature of the drug.
Furthermore, the percentage of R value seems to have no main
effects on the liquisolid thermograms. This is contrary with the type
and the percentage of the liquid vehicles. In the case of PEG200 liquisolid
formulations, a broader peak appearswhen the percentage of theweight
of norﬂoxacin to the weight of PEG200 is 40%w/w at 139.04 °C with a
small amount of enthalpy capacity equals to 27.92 J/g. Although this
Table 3
Flow properties of liquisolid powder mixtures.
Formulations CI% Position
PEG200 20%ww,R10 22.22 Passable
PEG200 20%w/w,R20 23.64 Passable
PEG200 40%w/w, R10 29.03 Poor
PEG200 40%w/w, R20 39.29 Very poor
Conventional 17.39 Good
Synperonic 20%w/w,R10 24.11 Passable
Synperonic 20%w/w, R20 21.21 Passable
Synperonic 40%w/w, R10 31.03 Poor
Synperonic 40%w/w, R20 35.38 poor
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PEG200, the reduction in melting temperature point improves that
there is a certain of reaction happened between the vehicle and the
drug. Complementarily with this, the broad small peak disappeared
completely when increasing the amount of PEG200 vehicle in the
liquisolid formulations.
Guyot et al. reached to the same conclusion in terms of disappear-
ance of the endothermic norﬂoxacin peak at 222 °C. However, due to
using another type of liquid vehicle (PEG6000) and changing the phar-
maceutical preparation to solid dispersion technique, another peak
appeared at 62 °C when the percentage of the surfactant exceeds 50%
with the drug [17]. On the other hand, very tiny peaks were indicated
at the samemelting temperature of norﬂoxacinwith very small enthalpy
capacities, which ranged from 0.08 J/g at 20%w/w norﬂoxacin/
Synperonic PE/L-61 to 0.61 J/g at 40%w/w norﬂoxacin/Synperonic PE/L-
61. This is accompanied with one or two temperature decrease (220–
221 °C). The probable reason for this is the less degree of solubility of
norﬂoxacin in the vehicle (0.167 mg/ml). However, this does not give
a negative effect on the dissolution proﬁle. On contrary, it enhances
the percentage of the drug release compared with PEG200 liquisolid
formulations as whole.
Finally, the sharp endothermic peak appears clearly in the case of the
conventional powder, where there is no added liquid vehicle to the
formulations. It appears at 221.37 °C with enthalpy equals to 0.9524 J/g,
indicating a slightly change in drug crystallinity compared with the
liquisolid formulations.3.2.3. Fourier transform infra-red spectroscopy (FTIR)
Figures from 5 to 10 provide information about IR spectra of pure
norﬂoxacin (Fig. 5), the carrier and the coating (Fig. 6), lubricant and dis-
integrate (Fig. 7), the liquid vehicles (Fig. 8), the PEG200 liquisolid formu-
lations (Fig. 9) and the Synperonic PE/L-61 liquisolid formulations
(Fig. 10). The last twoﬁgures provide a comparisonbetween the liquisolid
formulation, conventional powder and pure norﬂoxacin powder.
From Figs. 9 and 10, it is obvious that characteristic ﬁngerprint FTIR
peaks of norﬂoxacin between 1700 cm−1 and 1250 cm−1 facedmassive
changes in the IR spectra related to liquisolid formulations. These
changes are expressed in several ways, such as reduced in the intensity
of signal, shift or disappearance of the whole peaks, suggesting that
there is interaction between the drug and the excipients.
In addition to this, the decreased percentage of the transmittance
between 1190 cm−1 and 1000 cm−1 wavenumbers in liquisolid formu-
lations suggests a particular interaction between norﬂoxacin with
the liquid vehicles. For example, there is a simultaneous increase
of the absorptive intensity of these IR spectra when increasing the
percentage of PEG200 in the liquisolid formulations. The intensive
peak from this increase in the liquid concentration cannot be seen asTable 2
The solubility of norﬂoxacin in a range of surfactants and distilled water at room
temperature (24 °C).
Liquid vehicle Average of solubility (mg/ml) Standard deviation
PEG200 2.507 0.066
Span 80 1.997 0.266
PG 1.734 0.239
PEG300 1.547 0.132
Tween 20 1.085 0.056
Tween 80 0.954 0.251
Span 20 0.6374 0.033
PEG400 0.428 0.131
Cremophore EL 0.366 0.113
Pluronic L-35 0.35 0.194
Distilled water 0.34 0.03
Synperonic PE/L-61 0.167 0.006strong as PEG200 formulations in case of conventional formulations or
in Synperonic PE/L-61 formulations when the vehicle presents in less
percentages. This could lead to suggest a probability of intermolecular
hydrogen bonding formation between the drug and the liquid vehicle.
Supporting the presence of hydrogen bonds is the disappearance of
sharp vibrations between 1650 cm−1 and 1550 cm−1 in all liquisolid
formulations (PEG200 and Synperonic PE/L-61) compared with pure
norﬂoxacin. This region denotes the bending vibration of the secondary
amine functional group (R2NH). This indicates that there is hydrogen
bond between N\H functional group in norﬂoxacin and the hydrogen
molecule in hydroxyl group in the vehicle. Consequently, the formation
of hydrogen bonds between the drug and the vehicle contributes in
increasing the solubility of the drug in the vehicle, which reﬂectsmainly
on the dissolution proﬁles [10].
As a result, FTIR spectra analysis complieswithDSC results, indicating
a solubilisation of norﬂoxacin crystals in liquid vehicles, decreasing the
crystallinity of norﬂoxacin.3.3. Evaluation of norﬂoxacin liquisolid tablets
3.3.1. Drug content uniformity, tablet dimensions, hardness, tensile strength,
friability and disintegration tests
A summary of results expressed by the average and the standard
deviations of tablet hardness, tensile strengths, friability, disintegration
and drug content for all liquisolid (PEG200 and Synperonic PE/L-61)
and conventional tablets is presented in Table 4. British Pharmacopeia
speciﬁes the accepted limits of the percentage of the active ingredient
in tablets between 85% and 115% [9]. According to this, all liquisolid
(PEG200 and Synperonic PE/L-61) and conventional formulations areFig. 3.Differential scanning calorimetry for norﬂoxacin pure powder, conventional and all
liquisolid formulations.
Fig. 4. Differential scanning calorimetry for conventional and all liquisolid formulations
without pure norﬂoxacin powder.
Fig. 5. FTIR spectrum of pure norﬂoxacin powder.
Fig. 6. FTIR spectra for pure excipients (Avecil PH101 and Cab-o-sil M5DP).
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contents indicated that there is no signiﬁcant differences between
either conventional and PEG200 formulations (P= 0.430), conventional
and Synperonic PE/L-61 formulations (P = 0.293) or PEG200 and
Synperonic PE/L-61 formulations (P = 0.293). The reason of this could
be referred to the high percentage of the carrier excipient in the unit
dose of the PEG200 tablets (ranged between 71.2% and 74.6%), the
Synperonic PE/L-61 tablets (from 75.83% to 78.41%) and the convention-
al tablet (79.73%). This leads to increase in the surface area that absorbs
the liquid medication into the internal part of the carrier framework,
allowing a homogeneous distribution throughout the bed powder of
the batches [16]. As a result of this, all drug percentages are ranged
between over 90% and less 105%.
The reason for variations in the tablet thickness can be explained in
terms of the variation in theweights of the tablets,which are determined
to allow sufﬁcient tablet hardness with an appropriate disintegration
time (usually less than 5 min).
The tensile strength of the Synperonic PE/L-61 formulations show
more consistency (i.e. less variations) compared with the PEG200
formulations. This is expressed by F-test which determines a signiﬁcant
difference between The Synperonic PE/L-61 and PEG200 formulations
(P = 0.011 b 0.05). This is probably due to the fact that Synperonic
PE/L-61 formulations were prepared using compatible liquisolid test
which allows preparing the formulations at a plateau compression
forces with an optimum pactisity value (20 kg/g). As a result of this, it
determines lesser tensile strengths compared with the PEG200 formu-
lations, which were prepared depending on the acceptable ﬂowability
value for both carrier and coating materials by angle of slide test, not
allowing a sufﬁcient control in the compression forces.
From industrial perspective, it is important to balance between
disintegration time and tablet hardness. Moreover, there is a relation-
ship between tablet hardness and its porosity. Decreasing the porosity
among the particles in the tablets is due to increasing the compression
forces and the hardness of the tablets. Consequently, there is a decrease
in the intermolecular distance, promoting more formation of solid
bridges among the tablet particles [11].
In this study, the range of hardness is between 45.60 N and 91.94 N
(Table 4).
Using microcrystalline cellulose (Avicel PH101) as a carrier with
high percentages leads to close the surface and increase hydrogen bond-
ing between the molecules. This is due to the ability of the carrier to
exhibit plasticitywhich explains the deformation of particles undergoing
non-reversible changes of shape as a response to applied compression
forces [18].
The investigation of the percentages of weight loss in friability tests
demonstrates that the all formulations passed the BP speciﬁcations [9].
In other words, no formulations lost more than 1% from tablet weights,with nomarkedly cracked or broken tablets during the test. Consequent-
ly, liquisolid tablets have the ability to resist the expected abrasions
when applying further manufacturing processes.
For disintegration data, the averages of the time of the PEG200 for-
mulations is over 90 s, whereas the average of the Synperonic PE/L-61
formulations records a time less than 50 s. Table 4 presents the range of
the time of the PEG200 formulations between 91.6 and 275.6 s, while
the time of the Synperonic PE/L-61 formulations is between 30.3 and
62.5 s. Because of less variations in the case of the Synperonic PE/L-61
liquisolid formulations compared with the PEG200 liquisolid formula-
tions, the statistical analysis showed no signiﬁcant differences between
the PEG200 and the conventional formulations (P=0.06 N 0.05), where-
as there is a signiﬁcant difference (P = 0.01 b 0.05) in the case of the
comparison between the time of disintegration of the Synperonic PE/L-
61 and the conventional tablets. To sumup, all liquisolid formulations re-
corded disintegration times less than 5min, although the PEG200 formu-
lations recorded longer time than the Synperonic PE/L-61 formulations.
Nevertheless, all of them meet the BP speciﬁcations, which are less
than 15 min in the case of uncoated tablets [9]. Seeing rapid disintegra-
tion times through improving tablet dissolution proﬁles is important
due to the fast division that is provided into surface fragments, reaching
to higher surface areas for dissolution processes. Mentioning this would
drive toward specifying the reasons of the fast disintegration, which re-
lates to presenting bothmicrocrystalline cellulose and carmellose sodium
in high percentages in the tablet dosage forms. In the same direction,
PEG200 demonstrated slightly longer disintegration time, which can be
referred to the lower percentages of microcrystalline cellulose in the for-
mulations. In summary, the type of liquid vehicles, the percentage of the
Fig. 7. FTIR spectra for pure excipients (carmellose sodium and magnesium stearate).
Fig. 9. FTIR spectra for pure norﬂoxacin, conventional powder, and the all PEG200
liquisolid formulations.
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controlling the time of the liquisolid tablet disintegration.
3.3.2. In vitro dissolution
It is clear that the percentage of norﬂoxacin release in the acetate
buffer dissolution medium is signiﬁcantly higher than in the distilled
water dissolution medium (f2 b 26% for all comparisons between each
liquisolid and conventional formulations in the two dissolution media).
The percentage of the drug release was over 85% in all liquisolid and
conventional tablets after 90 min, whereas it was no more than 63% in
distilled water dissolution medium.
Fig. 11 shows all PEG200 liquisolid tablets with conventional tablets
in distilled water. In this proﬁle, the conventional tablet shows the
highest percentage of drug release compared with the other liquisolid
tablets. However, at the ﬁrst 20 min, tablets with 40% w/w norﬂoxacin:
PEG200 liquid medication with the both excipient ratios (R = 10 and
20) record higher percentage of norﬂoxacin release compared with
the conventional one. Then, the conventional dissolution proﬁle
continues raising over both liquisolid tablets. On the other hand, when
the percentage of norﬂoxacin: PEG200 liquid medication decreases,
the dissolution proﬁles decrease signiﬁcantly (f2 b 35% when compar-
ing the PEG200 formulations 20%w/w and 40%w/w in distilled water),
reaching to only 30% after 90 min. In Fig. 12, all PEG200 liquisolid and
conventional tablets record similar dissolution proﬁles with over 85%
drug release in the ﬁrst 30 min.
In the case of Synperonic EP/L-61 dissolution proﬁles (Figs. 13 and
14), the drug release from conventional tablets is still higher thanFig. 8. FTIR spectra for liquid vehicles (PEG200 and Synperonic PE/L-61).most of the Synperonic PE/L-61 liquisolid tablets, except a slightly
increase in one dissolution proﬁle, which drug: liquid medication per-
centage is at 40%w/w and the excipient ratio equals to 10, nevertheless
it is not a signiﬁcant increase in the drug release (f2 = 61.41%). The
liquisolid tablet (20%w/w, R = 20) shows a signiﬁcant decrease in
comparison with the conventional tablet (f2 = 44.7%). In general, all
Synperonic PE/L-61 proﬁles keep the same order of the PEG200 dissolu-
tion proﬁles, when comparing the liquisolid with the conventional
tablets in both dissolution media (Figs. 13 and 14).
Finally, the comparison between the dissolution proﬁles of the
Synperonic PE/L-61 liquisolid tablets and the PEG200 liquisolid tablets
having the same composition determine that there is no signiﬁcant
differences in all formulations, except the tablets having drug: liquid
medication percentage equals to 20%w/w and R = 10, where the
Synperonic PE/L-61 tablet has a signiﬁcantly higher norﬂoxacin release
(f2 = 44.04% in distilled water and 40.98% in acetate buffer).
From dissolution proﬁles, many points can be concluded. First of all,
the enhancement of norﬂoxacin in two liquisolid formulations (40%w/w
norﬂoxacin: PEG200 liquid medication, R = 10 and R = 20) compared
with the conventional tablets in distilled water dissolution medium
can probably be explained by Noyes–Whitney equation : dcdt ¼ DS Cs−Cð Þh
where dc/dt is the dissolution rate of the drug particles, S is the surface
area of the interface between the dissolving substance and the solvent,
D is the diffusion coefﬁcient, h is the thickness of the boundary layer of
the solvent at the surface of the dissolving substance, Cs is the massFig. 10. FTIR spectra for pure norﬂoxacin, conventional powder, and the all Synperonic PE/
L-61 liquisolid formulations.
Table 4
Tablet hardness, tensile strengths, disintegration time, friability and content uniformity for conventional and the all liquisolid tablets (average +/− standard deviation).
Formulations Hardness (N) T-strength (MPa) Disintegration (seconds) Friability % Content uniformity %
PEG200 20%ww,R10 51.97 +/− 3.75 0.880 +/− 0.189 275.6 +/− 61.5 0.474 94.83 +/− 1.6
PEG200 20%w/w,R20 91.93 +/− 21.5 1.508 +/− 0.368 192.8 +/− 70 0.405 104.73 +/− 5.1
PEG200 40%w/w, R10 66.93 +/− 42.5 1.123 +/− 0.697 148.2 +/− 72.8 0.842 94.90 +/− 3.1
PEG200 40%w/w, R20 45.60 +/− 7.18 0.707 +/− 0.085 91.7 +/− 11.4 0.724 96.74 +/− 7.5
Conventional 47.56 +/− 5.63 0.754 +/− 0.119 62.5 +/− 9.5 0.864 99.94 +/− 0.52
Synperonic 20%w/w,R10 46.85 +/− 3.01 1.172 +/− 0.083 49.2 +/− 6.9 0.304 98.62 +/− 5.6
Synperonic 20%w/w, R20 57.75 +/− 3.58 1.097 +/− 0.067 39.8 +/− 11.3 0.275 100.91 +/− 5.1
Synperonic 40%w/w, R10 48.27 +/− 2.9 1.206 +/− 0.064 40.3 +/− 4.4 0.167 100.49 +/− 1.7
Synperonic 40%w/w, R20 58.25 +/− 2.4 1.059 +/− 0.043 30.3 +/− 1.5 0.338 102.90 +/− 2.3
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tration of the substance in the bulk of the solvent.
From this equation, only two factors could affect the enhancement of
the drug release, which are the drug concentration gradient in the
diffusion layer (Cs− C) and the surface area of the interface between
the dissolving substance and the solvent (S). This is due to the speed
of the paddle that is constant (50 rpm) and the dissolution medium
(distilled water) that is the same for all the comparative tablet dissolu-
tion proﬁles. As a result, the thickness of the boundary layer (h) and the
diffusion coefﬁcient (D) are not included in this situation.
Regarding the surface area of the interface (S), it is directly propor-
tional to the dissolution rate of the drug. Consequently, the drug
dissolves in a water miscible liquid vehicle in the liquisolid tablets,
which has good wettability. This enhances the wetting characterization
of norﬂoxacin particles, increasing the surface area of the interface
between the liquid medication and the dissolution medium compared
with the surface area of the drug particles alone and the dissolution
medium in the case of the conventional tablets, which leads to the
increasing in the rate of norﬂoxacin release [19,20].
The second reason relates to the saturation solubility (Cs). At micro-
environment, there is a high possibility that an inﬁnite amount of
liquid-vehicle is to diffuse awaywith norﬂoxacinmolecule from liquisolid
particles, since the liquid vehicle works as co-solvent in order to improve
the solubility of the drug, leading to increase the concentration gradient
and the percentage of the drug release [7]. The third reason is the solubil-
ity of norﬂoxacin in PEG200, which is higher than the solubility of
the drug in either Synperonic EP/L-61 or distilled water. Thus, a certain
amount of PEG200 added to liquisolid tablets would increase the
dissolution rate of the drug [11].
To sum up, three main factors are able to participate in enhancing
the two PEG200 liquisolid formulations over the conventional in
distilled water; the increase in the surface area of the interface betweenFig. 11. Percentage drug released from PEG200 liquisolid and conventional tablets in
distilled water.the dissolving liquid medication and distilled water, the increase of the
saturation concentration at molecular level and the higher solubility of
norﬂoxacin in PEG200 surfactant compared with the solubility in
distilled water and Synperonic PE/L-61 co-polymer.
An interesting point that can be noticed from dissolution proﬁles is
that the percentage of drug release of the conventional tablets is higher
than most liquisolid tablets. This could be referred to the nature of
norﬂoxacin solid particles. This drug has a unique solid structure that
allows the pharmaceutical hydrate to be more water soluble from
anhydrous forms.
In general, existence of water molecule in solid state of drugs can
decrease the solubility of the drug because water molecule works to
increase the thermodynamic stabilization of the solid structure by the
interaction of water molecules. However, norﬂoxacin is exceptional to
this rule. This is due to that the hydrate formation of norﬂoxacin can
occur in the anhydrous state. In addition, the hydration can change
the interaction between norﬂoxacin molecules from hydrogen bonding
to ionic bonding by proton transfer process from COOH group to NH
group in the solid state. In other words, water molecules convert
the drug from neutral state to zwitterionic state which increases the
percentage of ionization of the drug and the percentage of dissolution
rate. Therefore, the tablet dissolution behaviour was adversely affected
by lower humidity [21]. As a result, these phenomena can explain the
improvement of the conventional tablet dissolution proﬁle over
liquisolid tablet proﬁles because the drug particles in the conventional
tablet are more exposed to water molecules compared to liquisolid
tablets.
To support this conclusion, dissolution tests were applied on liquid
medications consisting of either norﬂoxacin: PEG200 or norﬂoxacin:
Synperonic EP/L-61 alone without adding powder excipients. The
same concentrations of drug in the solvent that was used to prepare
liquisolid formulationwere used in these tests. Also, the samedissolutionFig. 12. Percentage drug released from PEG200 liquisolid and conventional tablets in
acetate buffer (pH = 4) dissolution medium.
Fig. 13. Percentage drug released from Synperonic PE/L-61 liquisolid and conventional
tablets in distilled water dissolution medium.
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with a paddle speed 50 rpm. The samples were measured at 15 and
30 min and the differences between the percentages of the drug
release at the withdrawn time were calculated. All the results were
summarised in Table 5 and supported with images (Fig. 15) taken after
30 min of the dissolution test starts.
Table 5 and Fig. 15 show clearly that there is a strong interaction
between norﬂoxacin particles and PEG200, preventingwater molecules
to enter the solid framework of the drug particles, and making the
percentage of norﬂoxacin release in dissolution medium from liquid
medication is less than conventional one. This interfering layer is not
seen in case of Synperonic PE/L-61 liquid medication (40%w/w) and a
fragile layer seen at concentration (20% w/w). As a result, the increase
volume of liquid vehicle, PEG 200, leads to decrease the percentage of
norﬂoxacin release as the constituted interfering layer prevent water
molecules to enter the liquid medication and induces the drug
molecules to form ionic bonds. Instead of this, the hydrogen bonds are
formed between the norﬂoxacin molecules themselves and the
PEG200 and to some extent with Synperonic PE/L-61.
Moreover, all liquisolid and conventional tablets show a percentage
of drug release less than 65% in distilled water. The reason of this in
addition to the low percentage of norﬂoxacin ionization in distilled
water is that the drug particles could precipitate inside the cavities of
the porous carrier on contact with liquid medication with the release
medium [22]. As a consequence of this, the drug release would retain.Fig. 14. Percentage drug released from Synperonic PE/L-61 liquisolid and conventional
tablets in acetate buffer (pH = 4) dissolution medium.This can be noticed when the increase of the excipient ratio (R = 20).
The higher percentage of Avicel PH101, the lower percentage of the
drug released in the dissolution medium. To overcome this problem,
poly vinyl pyrrolidone (PVP) can be used as a crystallization inhibitor.
Furthermore, PVP can also work as binder during compaction, which
leads to an increase of the liquid load factor [22].
Finally, these factors affecting the percentage of drug release
(e.g. Figs. 11 and 12) may enhance the oral bioavailability of these
formulations. For example, a solid dispersion formulation prepared at
ratio (20:80) norﬂoxacin: PEG6000presents better relative bioavailability
percentage (67%) when it is compared with powder of pure norﬂoxacin
(49%) [23]. In the same study, which was carried out on male albinos'
rabbits, the solid dispersion formulation showed maximum plasma
concentration closer to the plasma concentration of norﬂoxacin acetic
acid solution (pH = 4.5), which was recorded as 100% relative bioavail-
ability [23], led to conclude that in our study, the liquisolid formulations
of norﬂoxacin prepared with PEG200 are expected to enhance the drug
oral bioavailability. Additionally, it is reported that aqueous solubility
and the in-vitro dissolution proﬁle are not the unique explanation of
the behaviour of the oral bioavailability of norﬂoxacin, although they
help in indicating the physicochemical properties of the drug [23].
3.3.3. Kinetic model analysis of drug release
Table 6 presents the values of the squared correlation coefﬁcients for
liquisolid and conventional tablets, using zero order, ﬁrst order, Higuchi
and Hixson–Crowell kinetic release models. Broader reporting, the
highest R2 values were recorded when applying Higuchi or Hixson–
Crowell models for all types of tablets. Moreover, all liquisolid tablets
containing Synperonic PE/L-61 have higher R2 values form those includ-
ing PEG200. In addition to this, the data which is considered to build the
models are between 5 and 15min, whereas the rest points (i.e. from 20
to 90min) are excluded as the dissolution proﬁles reached to the steady
state where the drug release gives a straight parallel line to the time
axis. Paired t-test shows a slightly signiﬁcant difference between R2
values of both Hixson–Crowell and Higuchi models (P = 0.051 b 0.1),
where Hixson–Crowell recorded a slightly higher accuracy thanHiguchi
model. This situation is applied on all types of tablets, where all of them
recorded R2 values higher than 0.990.
Regarding Higuchimodel, Fick's law consists of a fundamental diffu-
sion background on which the release of norﬂoxacin into dissolution
medium depends. This law states that a driving forces coming from a
concentration gradient between the tablet and the bulk solution
diffuses the drug particles from tablet toward the dissolution medium
[14]. As a consequence of this hypothesis, the dispersion of norﬂoxacin
molecules in the liquid vehicles (PEG200 or Synperonic PE/L-61) would
affect the increasing of the saturation solubility (Cs) and the relative
concentration gradient (Cs-C) at different grades, allowing dissolving
of the drug particles in the dissolution medium [11].
On the contrary, Hixson–Crowell release model does not take Fick's
law in its assumptions. In otherwords, the diffusion of the drug particles
from the tablet is not included here. Hixson–Crowell model states that
there is a same effect of liquid agitation on all parts of the surface, and
there is no need to assume any particular shape of the drug crystal
because the model considers all of them to have a spherical shape
through the solution. Consequently, differences in the dissolution rate
from different faces of the tablet are negligible, and the main effects of
controlling the speed of the particle transformation are limited only to
the proportional change of the surface with the time and the agitation.
Therefore, the persistency of the drug particles to change its shape
assumption as a cubic root relationship with the time gives the quanti-
tative veriﬁcation to the releasemodel [15]. To someextent, the squared
correlation coefﬁcient values translate this assumption by dividing
the tablets into two main groups; the ﬁrst one includes all PEG200
liquisolid tablets which are less accurate, and the second includes
the Synperonic PE/L-61 liquisolid and conventional tablets which
are more accurate. As a result, the solubility of the drug in the liquid
Table 5
The percentage of drug release from the dissolution tests without powder excipients and the difference between them at 15 and 30 min.
Liquid vehicle 20%w/w (drug: liquid medication) 40%w/w (drug: liquid medication)
absa %Rb abs %R Differencec abs %R abs %R Difference
PEG200 15 min 15 min 30 min 30 min 15 min 15 min 30 min 30 min
0.352 33.531 0.410 39.056 5.525 0.407 38.770 0.454 43.247 4.477
0.431 41.056 0.495 47.153 6.097 0.457 43.533 0.570 54.297 10.764
0.346 32.959 0.445 42.390 9.431 0.509 48.487 0.600 57.155 8.669
Average = 7.017 7.970
ST DEVd = 2.109 3.201
Synperonic PE/L-61 0.590 56.203 0.741 70.587 14.384 0.467 44.486 0.757 72.111 27.625
0.379 36.103 0.575 54.774 18.671 0.586 55.822 0.832 79.255 23.434
0.538 51.249 0.800 76.207 24.958 0.470 44.772 0.730 69.539 24.767
Average = 19.338 25.275
ST DEV = 5.318 2.141
a abs: absorbance at 321 nm wavelength.
b %R: percentage of norﬂoxacin release in distilled water.
c Difference: differences between the %R at 15 and 30 min.
d ST DEV: standard deviation of the difference.
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shape during the dissolution test. Paired t-test signiﬁes the differ-
ence in the accuracy of the Hixson–Crowell model when compared
with the Higuchi model (P = 0.051 b 0.1). This gives a further
support to the Hixson–Crowell's assumption and explanations.
4. Conclusion
Norﬂoxacin releasing from liquisolid tablets is not necessarily faster
than conventional counterpart tablet. The chemical structure of the
hydrophobic drug and its interaction with the liquid vehicle determinea
c
b
d
Fig. 15. (a) Norﬂoxacin: PEG200 liquid medication (20%/w/w) after 30min in the mock dissolu
dissolution test. (c) Norﬂoxacin: Synperonic PE/L-61 liquid medication (40%/w/w) after 30 m
(20%w/w) after 30 min in the mock dissolution test.to large extent the dissolution behaviour of the drug. Furthermore, this
research represents that the solubility of the drug in the liquid vehicle
is not necessarily considered as a main effect in liquisolid dissolution
process.
On the other hand, using compatibility liquisolid test to indicate the
optimum load factor in the case of Synperonic PE/L-61 liquisolid formu-
lations providemore consistent qualiﬁed tablets comparedwith PEG200
liquisolid tablets, which was prepared depending on determining the
ﬂowability of liquid load potential of Avicel PH101 and Cab-O-Sil
M5DP using angle of slide test, although the weight of the unit dose is
lesser in the case of the PEG200 liquisolid formulations. Moreover,tion test. (b) Norﬂoxacin: PEG200 liquidmedication (40%/w/w) after 30 min in the mock
in in the mock dissolution test. (d) Norﬂoxacin: Synperonic PE/L-61 liquid medication
Table 6
Release parameters of norﬂoxacin liquisolid formulations.
Tablets/models Zero
order
First
order
Higuchi Hixson–Crowell
20%w/w drug/PEG200, R10 0.919 0.927 0.955 0.959
20%w/w drug/PEG200, R20 0.879 0.886 0.924 0.927
40%w/w drug/PEG200, R10 0.853 0.864 0.902 0.908
40%w/w drug/PEG200, R20 0.939 0.954 0.969 0.977
Conventional 0.999 0.999 0.996 0.992
20%w/w drug/Synperonic, R10 0.964 0.972 0.987 0.990
20%w/w drug/Synperonic, R20 0.998 0.999 0.999 0.998
40%w/w drug/Synperonic, R10 0.955 0.968 0.981 0.987
40%w/w drug/Synperonic, R20 0.985 0.990 0.998 0.999
167A.S. Suliman et al. / Powder Technology 257 (2014) 156–167both DSC thermograms and the vibrational spectra of FTIR reﬂected the
state of the crystallinity of the norﬂoxacin,which disappeared in liquisolid
formulations, and the possibility of hydrogen bond formation with liquid
vehicle, respectively. Finally, this paper suggests making further studies
on using PVP in liquisolid formulations due to its ability to work as a
crystallizing inhibitor, which probably increases the percentage of
norﬂoxacin release in distilled water as a dissolution medium.References
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